MediciNova Announces Proposed Underwritten Public Offering of Common Stock
2018年2月8日 - 6:01AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number:4875), announced today that it intends
to offer shares of its common stock in an underwritten public
offering. All of the shares of common stock to be sold in the
offering will be offered by MediciNova. MediciNova intends to
grant the underwriters a 30-day option to purchase up to an
aggregate of an additional 15% of the shares of its common stock
offered in the public offering. The offering is subject to
market and other conditions and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
MediciNova intends to use the net proceeds received from the
offering primarily to continue to fund the development of its
MN-166 (ibudilast) and MN-001 (tipelukast) programs, including a
Phase 3 clinical trial of MN-166 (ibudilast) for the treatment of
progressive MS, and for working capital and general corporate
purposes, including support for MediciNova’s continuing research
and development of its product candidates and research programs,
clinical trials, commercialization activities and business
development activities. MediciNova may use a portion of the net
proceeds for acquisitions of businesses, products, technologies or
licenses that are complementary to its business, although
MediciNova has no present commitments or agreements to do so.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg
Thalmann Financial Services Inc. (NYSE American:LTS), is acting as
sole book-running manager of the offering. B. Riley FBR, Inc.
is acting as lead manager of the offering.
The offering is made pursuant to a shelf registration statement
on Form S-3 (File No. 333-220593) that was filed by MediciNova with
the Securities and Exchange Commission (SEC) and was declared
effective on October 2, 2017. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the SEC’s
website at https://www.sec.gov/. When available, copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the offering may be obtained from Ladenburg Thalmann
& Co. Inc., 277 Park Avenue, 26th Floor, New York, NY 10172, or
by email at prospectus@ladenburg.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. Any offer, if at all, will be made
only by means of the prospectus supplement and accompanying
prospectus forming a part of the effective registration
statement.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company
founded upon acquiring and developing novel, small-molecule
therapeutics for the treatment of diseases with unmet medical needs
with a primary commercial focus on the U.S. market. MediciNova's
current strategy is to focus on MN-166 (ibudilast) for neurological
disorders such as progressive MS, ALS, glioblastoma and substance
dependence and addiction (e.g., methamphetamine dependence, opioid
dependence, and alcohol use disorder) and MN-001 (tipelukast) for
fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and
idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline
also includes MN-221 (bedoradrine) for the treatment of acute
exacerbation of asthma and MN-029 (denibulin) for solid tumor
cancers. MediciNova is engaged in strategic partnering and
other potential funding discussions to support further development
of its programs. For more information on MediciNova, Inc., please
visit www.medicinova.com.
Forward Looking Statements
Statements in this press release that are not historical in
nature constitute forward-looking statements within the meaning of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including statements regarding MediciNova’s
expectations with respect to its proposed offering, its intention
to grant the underwriters an option to purchase additional shares
and its intended use of proceeds from the offering. These
forward-looking statements include, without limitation, statements
regarding the future development and efficacy of MN-166, MN-221,
MN-001, and MN-029. These forward-looking statements may be
preceded by, followed by or otherwise include the words "believes,"
"expects," "anticipates," "intends," "estimates," "projects,"
"can," "could," "may," "will," "would," “considering,” “planning”
or similar expressions. These forward-looking statements involve a
number of risks and uncertainties that may cause actual results or
events to differ materially from those expressed or implied by such
forward-looking statements. Factors that may cause actual results
or events to differ materially from those expressed or implied by
these forward-looking statements include, but are not limited to,
risks of obtaining future partner or grant funding for development
of MN-166, MN-221, MN-001, and MN-029 and risks of raising
sufficient capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2016 and its subsequent periodic reports on Form
10-Q and current reports on Form 8-K. Undue reliance should not be
placed on these forward-looking statements, which speak only as of
the date hereof. MediciNova disclaims any intent or obligation to
revise or update these forward-looking statements.
INVESTOR CONTACT: |
Geoff
O'BrienVice PresidentMediciNova, Inc.info@medicinova.com |
|